The National Mesothelioma Audit (NMA) is commissioned and funded by Mesothelioma UK, a charity that provides specialist mesothelioma information and improved care.
What we are doing
Commissioned by and working in partnership with Mesothelioma UK to deliver the national mesothelioma audit (NMA), we have published a number of audit reports to raise the profile of this asbestos-related cancer and to make recommendations on improving the outcomes for mesothelioma patients.
There are four main aims for the mesothelioma audit:
- maintain and enhance the profile of mesothelioma, a disease with poor outcome and variation in care
- build upon the recommendations of the previous mesothelioma report and allow organisations to measure and demonstrate improvement over time
- embed a process of data collection for mesothelioma in clinical teams linked to an infrastructure that has a robust long-term future
- set new standards for mesothelioma.
What is mesothelioma?
Malignant mesothelioma (MM) is a type of cancer that develops over a long period of time and commonly originates in mesothelial cells found in the thin membrane (pleura) that lines the lungs and the inside of the chest wall (malignant pleural mesothelioma – MPM). Mesothelioma can also affect the similar peritoneal membrane within the abdominal cavity (peritoneal mesothelioma – PM). Approximately 2,500 people per year are diagnosed in the UK.